Alterola Biotech, Inc. (ABTI) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
47 HAMILTON SQUARE BIRKENHEAD MERSEYSIDE, CH41 5AR |
| State of Incorp. | |
| Fiscal Year End | March 31 |
| Industry (SIC) | 2833 - Medicinal Chemicals and Botanical Products (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 9/30/2024 MRQ | 3/31/2024 | 12/31/2023 MRQ | 3/31/2023 | 3/31/2022 | 9/30/2020 | 9/30/2019 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 3 | 3 | 9 | 64 | |||||
| Cash and cash equivalents | 3 | 3 | 9 | 64 | |||||
| Receivables | 2 | ||||||||
| Inventory, net of allowances, customer advances and progress billings | 1 | 1 | 1 | 1 | |||||
| Inventory | 1 | 1 | 1 | 1 | |||||
| Intangible current assets | |||||||||
| Other undisclosed current assets | 227 | 63 | 15 | ||||||
| Total current assets: | 4 | 4 | 237 | 128 | 15 | 2 | |||
| Noncurrent Assets | |||||||||
| Deferred costs | |||||||||
| Deferred income tax assets | 189 | ||||||||
| Other undisclosed noncurrent assets | 11,950 | 12,000 | |||||||
| Total noncurrent assets: | 12,140 | 12,000 | |||||||
| Other undisclosed assets | 12 | ||||||||
| TOTAL ASSETS: | 4 | 4 | 12,377 | 12,128 | 15 | 15 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 1,188 | 1,114 | 867 | 939 | 336 | 180 | |||
| Employee-related liabilities | ✕ | ✕ | ✕ | ✕ | 300 | 180 | |||
| Accounts payable | 825 | 804 | 612 | 543 | |||||
| Accrued liabilities | 362 | 311 | 255 | 396 | 36 | ||||
| Debt | 146 | 244 | 1,260 | 164 | |||||
| Other undisclosed current liabilities | 98 | 2 | 37 | ||||||
| Total current liabilities: | 1,333 | 1,358 | 2,127 | 1,202 | 338 | 217 | |||
| Noncurrent Liabilities | |||||||||
| Other undisclosed noncurrent liabilities | 154 | ||||||||
| Total noncurrent liabilities: | 154 | ||||||||
| Total liabilities: | 1,333 | 1,358 | 2,281 | 1,202 | 338 | 217 | |||
| Equity | |||||||||
| Equity, attributable to parent | (1,330) | (1,355) | 10,096 | 10,926 | (323) | (203) | |||
| Common stock | 1,383 | 1,383 | 807 | 803 | 130 | 117 | |||
| Additional paid in capital | 9,664 | 9,664 | 18,928 | 18,080 | 769 | 652 | |||
| Accumulated other comprehensive income (loss) | 40 | 11 | (63) | 15 | |||||
| Accumulated deficit | (12,416) | (12,441) | (9,576) | (7,971) | (1,222) | (971) | |||
| Other undisclosed equity, attributable to parent | 29 | ||||||||
| Equity, attributable to noncontrolling interest | |||||||||
| Total equity: | (1,330) | (1,355) | 10,096 | 10,926 | (323) | (203) | |||
| TOTAL LIABILITIES AND EQUITY: | 4 | 4 | 12,377 | 12,128 | 15 | 15 | |||
Income Statement (P&L) ($ in thousands)
| 9/30/2024 TTM | 3/31/2024 | 12/31/2023 TTM | 3/31/2023 | 3/31/2022 | 9/30/2020 | 9/30/2019 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues (Other Income) | 79 | |||||||
| Gross profit: | 79 | |||||||
| Operating expenses | (2,108) | (496) | (1,897) | (6,471) | (330) | (258) | ||
| Other undisclosed operating loss | (79) | |||||||
| Operating loss: | (2,108) | (496) | (1,897) | (6,471) | (330) | (258) | ||
| Nonoperating income (expense) (Other Nonoperating Income (Expense)) | (266) | (1,163) | 79 | (0) | ||||
| Interest and debt expense | (0) | |||||||
| Other undisclosed loss from continuing operations before equity method investments, income taxes | ||||||||
| Loss from continuing operations before income taxes: | (2,374) | (1,659) | (1,897) | (6,471) | (251) | (259) | ||
| Income tax expense | (85) | (82) | ||||||
| Other undisclosed income from continuing operations | ||||||||
| Loss from continuing operations: | (2,374) | (1,659) | (1,897) | (6,471) | (336) | (341) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | (6,471) | (336) | (341) | |
| Other undisclosed net loss | ||||||||
| Net loss: | (2,374) | (1,659) | (1,897) | (6,471) | (336) | (341) | ||
| Net income attributable to noncontrolling interest | ||||||||
| Other undisclosed net income attributable to parent | 278 | 155 | 85 | 83 | ||||
| Net loss available to common stockholders, diluted: | (2,374) | (1,381) | (1,742) | (6,471) | (251) | (259) | ||
Comprehensive Income ($ in thousands)
| 9/30/2024 TTM | 3/31/2024 | 12/31/2023 TTM | 3/31/2023 | 3/31/2022 | 9/30/2020 | 9/30/2019 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (2,374) | (1,659) | (1,897) | (6,471) | (336) | (341) | ||
| Other comprehensive loss | ||||||||
| Comprehensive loss: | (2,374) | (1,659) | (1,897) | (6,471) | (336) | (341) | ||
| Comprehensive income (loss), net of tax, attributable to noncontrolling interest | (137) | |||||||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (28) | (146) | ||||||
| Comprehensive loss, net of tax, attributable to parent: | (2,402) | (1,806) | (2,034) | (6,471) | (336) | (341) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.